Merck Ends Development of Two Potential COVID-19 Vaccines
The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies.
Related Articles
Diverticular Disease: Diagnosis and Management
This concise guideline summary covers the diagnosis and management of diverticular disease in people aged 18 years and over
PROS: Early Diagnosis and New Therapeutic Options
New therapeutic options are available for PIK3CA-related overgrowth spectrum, a range of disorders most commonly seen in children and often difficult to diagnose.
Adverse Pregnancy Outcomes Linked to Premature Mortality for Moms
The findings show a need for better care of previously pregnant patients, years after giving birth.
Diabetes: Diabetic Foot Problems
This summary covers preventing and managing foot problems in children, young people, and adults with diabetes. It aims to reduce variation in practice, including antibiotic…
Too Little Sleep Raises Health Risks for Teens With T1D
Sleeping for more than 7 hours at night may improve cardiometabolic health in patients with type 1 diabetes, especially teenagers, showed an analysis.
Earlier Inclisiran Gives Better Long-Term LDL Reductions
Results of VICTORION-INITIATE study suggest better results with inclisiran first and highlight “stunning undertreatment” of cholesterol in usual care of patients with CVD.
No Routine Cancer Screening Option? New MCED Tests May Help
Early data suggest that several new multicancer early detection tests can identify a range of cancers that lack routine screening options.
Patient âgé diabétique de type 2 : nouveautés dans la prise en charge
La prise en charge du patient diabétique de plus de 75 ans constitue un chapitre essentiel de la dernière révision de la prise de position…
Depression, Children: Identification and Management
This summary covers assessing people aged 5–18 years for depression and appropriate management strategies based on severity
Single-Dose Zilebesiran Cuts BP Out to 6 Months: KARDIA-2
This phase 2 study supports the potential for combining biannual dosing of zilebesiran with standard-of-care antihypertensives to achieve additive blood pressure reductions.